Navigation Links
Key immune cell may play role in lung cancer susceptibility
Date:9/21/2012

Why do many heavy smokers evade lung cancer while others who have never lit up die of the disease? The question has vexed scientists for decades.

Now, new research at Washington University School of Medicine in St. Louis suggests a key immune cell may play a role in lung cancer susceptibility. Working in mice, they found evidence that the genetic diversity in natural killer cells, which typically seek out and destroy tumor cells, contributes to whether or not the animals develop lung cancer.

The research is published in September in Cancer Research.

"Overall, humans are genetically very similar but their immune systems are incredibly diverse," explains senior author Alexander Krupnick, MD, a thoracic surgeon at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. "Our findings add to the growing body of evidence suggesting that innate differences in immunity may determine not only a person's susceptibility to colds but also to lung cancer."

Based on the findings in mice, Krupnick says he and his colleagues now are studying whether humans have a similar genetic diversity in their natural killer cells. As part of a new clinical study, they're analyzing the blood of heavy smokers with and without lung cancer and never-smokers with and without lung cancer to look for differences.

"We want to know whether heavy smokers who don't get lung cancer have natural killer cells that are somehow better at destroying newly developing lung cancer cells," says Krupnick, associate professor of surgery. "And, by comparison, do patients who have never smoked but develop lung cancer have weak natural killer cells?"

For the mouse study, the scientists evaluated three groups of mice with varying susceptibilities to lung tumors. After the mice were exposed to a carcinogen that causes lung cancer, one group readily developed the disease while another showed little evidence of the tumors. A third group experienced moderate tumor growth.

When the researchers depleted natural killers cells from the mice using an antibody, those that had been resistant to lung cancer developed large, aggressive tumors.

Further, in mice susceptible to lung cancer, the scientists showed that manipulating the immune system with a bone marrow transplant could significantly block the development of lung cancer. Their studies indicate that natural killer cells, not other types of immune cells like T cells or inflammatory cells, are responsible for this phenomenon.

In other types of cancers, including those of the breast, colon and prostate, T cells are capable of destroying tumor cells. But in lung cancer, scientists suspect that T cells become inactivated, which may give natural killer cells a more prominent role.

The researchers also traced the genetic diversity of the natural killer cells in the mice to a region of chromosome 6, which includes numerous genes that influence the effectiveness of these cells.

Moving forward, Krupnick and his team want to learn whether natural killer cells influence lung cancer susceptibility in people. "We need to identify those patients who are resistant to lung cancer and ask, 'What is unique about their natural killer cells are they more potent or do they produce more of them than people with lung cancer?' The answer will determine our next steps."


'/>"/>

Contact: Caroline Arbanas
arbanasc@wustl.edu
314-286-0109
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Feeding microbials to chickens leads to mysterious immune response
2. Researchers improve gene therapy technique for children with immune disorder
3. New grant awards aim to prevent autoimmune diseases
4. Immune system protein could explain pancreatitis
5. Cancer turns off important immune cells, complicating experimental vaccine therapies
6. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
7. In war with superbugs, Cedars-Sinai researchers see new weapon: Immune-boosting vitamin
8. New Immune-Deficiency Illness Emerging in East Asia
9. Immune responses can be generated locally within human melanoma skin metastases
10. Mount Sinai researchers discover new target for vaccine development in abundant immune cells
11. Mouse With Human-Like Immune System Could Advance AIDS Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: